NRAS mutation status is an independent prognostic factor in metastatic melanoma (pages 4014–4023)
John A. Jakob, Roland L. Bassett Jr., Chaan S. Ng, Jonathan L. Curry, Richard W. Joseph, Gladys C. Alvarado, Michelle L. Rohlfs, Jessie Richard, Jeffrey E. Gershenwald, Kevin B. Kim, Alexander J. Lazar, Patrick Hwu and Michael A. Davies
Article first published online: 16 DEC 2011 | DOI: 10.1002/cncr.26724
Patients who have metastatic melanoma with mutations of the v-raf murine sarcoma viral oncogene homolog B1 (BRAF) or neuroblastoma RAS viral (v-ras) oncogene homolog (NRAS) genes are more likely than those with the wild-type of both genes to have central nervous system involvement at the diagnosis of distant metastases. NRAS mutation status is an independent predictor of shorter survival after the diagnosis of stage IV melanoma.